Pharmaceutical Coverage & Reimbursement Conference

 

Recognizing the Impact of Health Policy Changes on Pharmaceutical Reimbursement and Assuring Successful Coverage through Comparative and Cost Effectiveness Strategies

 

Held November 16-17, 2009 in Washington, DC

 

This conference was designed to provide executives with case study examples and best practices from leading pharmaceutical and biotechnology companies currently achieving reimbursement success with their new therapies. Sessions will delve into health policy changes, and how they are impacting the industry, and will provide real-time solutions to the challenges that companies face in these uncertain times.

 

Presentations addressed the increased importance of comparative effectiveness studies, highlighting companies and products that have successfully obtained reimbursement with the aid
of blinded studies, randomized clinical trials and long-term, real-life health economic studies. Other topics that will be addressed during the program are merging markets currently impacting the industry, generic competition, as well as strategies for working with private payers and pricing.

 

Speakers Included

 

Larry Atkins
Executive Director of Public Policy & Reimbursement
Schering-Plough

 

Michael J. Ruggiero
Senior Director, Government Policy & External Affairs
Astellas Pharma US, Inc

 

Dr. Josephine Sollano
Global Head Outcomes Oncology Business Unit
Pfizer

 

Peter Pitts
President and Co-founder
Center for Medicine in the Public Interest

 

And more...

 

Topics Included

• Impact of health care reform on the pharmaceutical industry
• Updates on changes in CMS payment structures and rebate programs
• Development of strategic drug pricing campaigns
• Overcoming the increasing threats from generic competition
• Understanding processes for payment from private payers
• Optimizing payment through early-decision making in R and D
• Recognizing the global context of comparative effectiveness
• Evidence threshold requirements for payment: private & public
• Bringing together health economics, market access & reimbursement
• Medicare reimbursement updates on Parts A, B, C & D
• Addressing the impact of potential third party comparative effectiveness studies
• Recent litigation related to pharma pricing and reimbursement
• Designing clinical studies to support reimbursement efforts
• Quality of life and health economics indicators
• Reimbursement Strategies for New Therapies
• Future of Drug Pricing
• Providing clinical Data to support reimbursement
• How the aging population will affect the pharma industry

 

To more information on this program please contact:

 

Paul Hernandez, Marketing Manager
phernandez@Q1productions.com
312-602-9684